Skip to main content
. 2017 May 31;10(4):535–545. doi: 10.1016/j.tranon.2017.04.004

Figure 3.

Figure 3

The therapeutic potential of 212Pb-panitumumab was directly compared with 212Pb-trastuzumab and 212Pb-cetuximab. The 212Pb-labeled mAbs (10 μCi per mouse) were administered i.p. to athymic mice bearing LS-174T i.p. tumor xenografts. Two other groups of mice were included in the experiment. One group received 10 μCi of 212Pb-HuIgG, a nonspecific control, and the other was left untreated.